Please be advised that Cytox Limited was placed into Liquidation on 4 January 2024, with Simon Farr and Anthony Collier of FRP Advisory Trading Limited being appointed Joint Liquidators of the Company. If you are owed money by Cytox Limited, or require further information about the Liquidation, please do not hesitate to contact email@example.com.
Sep 15, 2015
Cytox CEO keynote speaker at UKTI thought leadership conference on dementia
Oxford, UK. Cytox congratulates Professor John Hardy (UCL Institute of Neurology, London) on receiving the $3 million (£2 million) Breakthrough Prize in Life Sciences for his pioneering research into the genetic causes of Alzheimer’s disease, other forms of dementia and Parkinson’s disease. The Breakthrough Prize in Life Sciences honours ‘transformative advances toward understanding living systems and extending human life’. This is the first time that the prize has been awarded to a UK researcher.
‘We are proud to be associated with John Hardy’, commented Richard Pither, CEO Cytox Ltd, ‘He is a much valued member of our Scientific Advisory Panel, and is a key part of the consortium we lead that was awarded Innovate UK funding earlier this year to investigate the application of SNP profiling to risk stratification in Alzheimer’s disease.’
The Breakthrough Prize is backed by Facebook chief executive Mark Zuckerberg and Google co-founder Sergey Brin, among others.